TRVN קפיטליזציה חשבונאית Trevena

Trevena, Inc. (TRVN) revenues rely on the commercialization of Olivir for hospital pain therapy and expansion in Asia through partners, with the figure standing at -0.02. This price chart reflects the dynamics of the biopharmaceutical company, which develops safe targeted alternatives to traditional CNS analgesics. The business is currently optimizing resources and conducting targeted preclinical tests of new molecules following a revision of its research programs.

For Trevena, Inc., which utilizes outsourcing for production and testing, the book capitalization value on GURU.Markets reflects the dynamics of net equity without redundant fixed assets. This indicator is calculated as the difference between all assets and liabilities, allowing the investor to assess the real speed of resource accumulation and the risk of declining total returns in the event of inefficient expansion of the asset base.